DOCSLIB.ORG

From Celebrex to a Novel Class of Phosphoinositide-Dependent Kinase 1 (Pdk-1) Inhibitors for Androgen-Independent Prostate Caner

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
From Celebrex to a Novel Class of Phosphoinositide-Dependent Kinase 1 (Pdk-1) Inhibitors for Androgen-Independent Prostate Caner FROM CELEBREX TO A NOVEL CLASS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK-1) INHIBITORS FOR ANDROGEN-INDEPENDENT PROSTATE CANER DISSERTATION Presented in Partial Fulfillment of the requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Jiuxiang Zhu, M.S. * * * * * The Ohio State University 2005 Dissertation Committee: Approved by Professor Ching-Shih Chen, Advisor Professor Robert Brueggemeier Advisor Professor Pui-Kai (Tom) Li Graduate Program in Pharmacy Professor Matthew D. Ringel ABSTRACT Celebrex, a nonsteroidal anti-inflammatory drug (NSAID, cyclooxygenase-2 inhibitor), was reported to induce apoptosis in the prostate cancer cell line PC-3 at 50µM. Early research from our laboratory demonstrated that this apoptotic inducing effect was independent of its COX-2 inhibitory activity. Further investigation showed that PDK-1 was a major protein targeted by celebrex in PC-3 cells to induce apoptosis. However, celebrex was very weak in inhibiting PDK-1 with IC50 of 48µM. To improve its potency, two series of analogs were designed and synthesized. In the first series of 24 compounds, the 5-position methylphenyl moiety of celebrex was replaced by various aromatic ring systems to explore the optimal hydrophobic group. OSU02067 (IC50=9µM) with phenanthrene at the 5-position was the best inhibitor among this series and was selected as the lead compound for further modification. Enzyme kinetics study of PDK-1 inhibition by celebrex indicated that it competed with ATP for binding. Docking of OSU02067 into the ATP binding domain of PDK-1 showed that the sulfonamide moiety hydrogen bonded to hinge region residue Ala162. Considering the importance of H-bonding, the sulfonamide moiety was substituted with various heteroatom-rich functional groups in the 2nd series of 12 compounds. OSU03012 and OSU03013 stood out as the most potent analogs with IC50s ii of 5µM and 2µM, respectively. Such improvement was partly attributed to an additional H-bond formed with hinge region residue Ser160. Exposure of PC-3 cells to these two agents (5µM or higher) led to significant decreases in Akt and p70s6k kinase activity (both are downstream substrates of PDK-1) and an increase in apoptosis evidenced by nucleosome formation and PARP cleavage. As OSU03012 was tolerated well by nude mice at a dose of 200mg/kg, it was chosen for further study. In primary chronic lymphocytic leukemia cells and the breast cancer cell line, MDAMB453, the compound induced apoptosis. In addition, Tseng et. al. showed that OSU03012 was equally potent in imatinib-resistant and -sensitive CML cells with IC50 of 6µM. OSU03012 was able to sensitize mutant resistant cells (Ba/F3p210E255K and Ba/F3p210T315I) to imatinib partly because of the concerted effect on phospho-Akt. Currently, OSU03012 is being studied in lung, thyroid, ovarian and bladder cancers and preclinical studies are underway (including toxicology, pharmacokinetics and pharmacodynamics). Future structure modification of OSU03012 is expected to be pursued in the following three aspects. Hydrophobic pockets behind the adenine binding domain and at the C-terminal lobe below the ribose binding pocket will be explored. Crystal structures of PDK-1 with this class of inhibitors are needed to provide insights into structure-based design. Adsorption, distribution, metabolism and execretion will be integrated into inhibitor design to achieve clinically applicable drug candidates. iii Dedicated to my grandparents, parents and brother iv ACKNOWLEDGMENTS • I would like to acknowledge Dr. Chen for his guidance, constant encouragement, support and for providing excellent working environment for his students • I would also like to express my sincere appreciation for the faculty of the division, especially Drs. Brueggemeier and Li, for all their help and advice • I want to thank Kathy Brooks and Kelli Ballouz for being able to solve any problem and make graduate studies going smoothly • Colleagues and friends: Drs. Kulp, Song, Johnson, Lin and Wang, Ho-Pi, Yvette, Ping-Hui, Ya-Ting, Joe, Chung-Wai, Yeng-Jeng, Kuen-Feng, Leo, Qiang, Jim, Chang-Shi, Nicole and Jack for help in all kinds of experimental details, invaluable discussion about a variety of scientific topics and proofreading thesis draft. • Xiaohui and Yan for having lots of funs together and making graduate studies memorable. v VITA 1993-1997 B.S. Pharmaceutical Science Beijing University, China 1997-2000 M.S. Natural Product Chemistry Peking Union Medical College, China 2000-Present Graduate Teaching and Research Associate College of Pharmacy, Ohio State University PUBLICATIONS 1. Jiuxiang Zhu, Jui-Wen Huang, Joseph Fowble, Ping-Hui Tseng, Chung-Wai Shiau, Yeng-Jeng Shaw, Samuel K. Kulp, and Ching-Shih Chen From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of Potent Akt-Targeted Antitumor Agents. Cancer Research, 2004;64(12):4309-18 2. Jiuxiang Zhu, Xueqing Song, Ho-pi Lin, Donn C. Young, Shunqi Yan, Victor E. Marquez, Ching-shih Chen Using Cyclooxygenase-2 Inhibitors as Molecular Platforms to Develop a New Class of Apoptosi s-inducing Agents. Journal of the National Cancer Institute 2002, 94(23), 1745-17 3. Amy J. Johnson, Lisa L. Smith, Jiuxiang Zhu, Nyla A. Heerema, Sara Jefferson, Michael Grever, Ching-shih Chen, John C. Byrd. A Novel Celecoxib Derivative Induces Apoptosis in Primary CLL Cells and Transformed B-cell Lymphoma via a Caspase and Bcl-2 Independent Mechanism. Blood, 2004, Sep 28. 4. Haiming Ding, Chunhua Han, Jiuxiang Zhu, Ching-Shih Chen, Steven M.D’Ambrosio. Celecoxib Derivatives Induce Apoptosis via Disruption of Mitochondrial Membrane Potential and Activation of Caspase 9. Int. J Cancer., 2004 Oct 21. FIIELDS OF STUDY Major Field: Pharmacy vi TABLE OF CONTENTS Page Abstract……………………………………………………………………………........ii Dedication……………………………………………………………………………...iv Acknowledgments..…………………………………………………………………......v Vita……………………………………………………………………………………..vi List of Tables…………………………………………………………………………...ix List of Figures………………………………………………………………………......x Abbreviations…………………………………………………………………………xiv Chapter 1 Introduction………………………………………………………………….1 1.1 Hormone-Refractory Prostate Cancer (HRPC) and Therapies……………..1 1.2 PI3K/PDK-1/Akt Signaling Pathway ……………………………………...5 1.3 Protein Kinases (PKs) and Their Inhibitors………………………………...9 1.3.1 Kinases and Cancer…………………………………………………...9 1.3.2 Protein Kinase Inhibitors (PKIs)…………………………………….12 1.4 Cyclooxygenase-2 (COX-2) Inhibitors as Anti-cancer Agents…………....15 Chapter 2 Molecular Target(s) for Celebrex and Project Design……………………...27 2.1 Molecular Target of Celebrex…………………………………………….27 2.1.1 COX-2 Independent Mechanism…………………………………….27 2.1.2 PDK-1, a Major COX-2 Independent Target for Celebrex………….29 2.2 Aims and Project Design………………………………………………….30 Chapter 3 Design, Synthesis and Biological Activities of the1st Series of Celebrex Derivatives…………………………………………..……………………...39 3.1 Design of the 1st Series of Derivatives……………………………..……...39 3.2 Synthesis of the 1st Series of Derivatives…...……………………………..40 3.3 Structures of the Analogs and Their Biological Activities…….…..……...41 3.4 OSU02067………………………………………………………………....42 3.4.1 Effect on Downstream Protein Akt…………………………………...42 3.4.2 Cellular Effect of OSU02067…………………………………………42 3.4.3 In vivo Study of OSU02067………………………………………......43 vii Chapter 4 Structure-Based Design of PDK-1 Inhibitors………………………………49 4.1 Crystal Structure of PDK-1 Catalyic Domain in Complex with ATP…….49 4.2 Docking of OSU02067 to ATP Binding Domain and Design of the 2nd Series Analogs….……………………………………………..……………….50 4.3 Synthesis of the 2nd Series of Compounds……………………………..….52 4.4 Optimal Compounds-OSU03012 and OSU03013………………………...54 4.5 In vitro Effect of OSU03012 and OSU03013 in PC-3……………………55 4.5.1 Effects on Downstream Proteins Akt and p70S6K…………………..55 4.5.2 Cellular Effects of OSU03012 and OSU03013…………………….55 Chapter 5 Application of OSU03012 to Other Cancers……………………………….71 5.1 In Primary Chronic Lymphocytic Leukemia (CLL)………………………71 5.2 In Breast Cancer cells MDAMB453…..………………………..…………71 5.3 In Gleevec Resitant Chronic Myelogenous Leukemia (CML) Cells……...72 Chapter 6 Conclusions and Future Directions………………………………………...73 6.1 Conclusions……………………………………………………………...73 6.2 Future Directions………………………………………………………..73 6.3 Concerns about Anticancer Drug Development………………………...77 6.3.1 Specific PKIs versus Non-Specific (or Broad Spectrum) PKIs…...78 6.3.2 Targeted Cancer Therapy-Lessons from Gefitinib Clinical Trial…79 Chapter 7 Experimental Methods and Material……………………………………….83 7.1 Synthesis of the 1st Series of Compounds……………………………..…..83 7.1.1 Preparation of Starting Material for Synthesis of Compound 1-4….83 7.1.2 Preparation of Starting Material for Synthesis of Compound 10-20.84 7.1.3 General Procedure…………………………………………………..85 7.2 Synthesis of the 2nd Series of Compounds………………………………...87 7.3 Nomenclatures, 1H NMR (proton nuclear magnetic resonance), and HRMS (high resolution mass spectrometry) Characterizations of Compounds 1 – 36………………………..………………..………………….93 7.4 PDK-1 Kinase Assay……………………………………………………...93 7.5 Cell Viability Assay……………………………………………………….94 7.5.1 Cell culture………...………………………………………………..94 7.5.2 MTT Assay………………………………………………………….94 7.6 Immunoblotting……………………………………………………………95 7.7 Immunoprecipitated Akt Kinase Assay…………………………………....96 7.8 Immunoprecipitated p70S6K Kinase Assay………………………………...96 7.9 Cell Death Detection ELISA………………………………………………97 7.10 Molecular Modeling……………………………………………………..98 Bibliography………………………………………………………………………….108 viii
Load more

Recommended publications
  • Targeting Fibrosis in the Duchenne Muscular Dystrophy Mice Model: an Uphill Battle
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427485; this version posted January 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Title: Targeting fibrosis in the Duchenne Muscular Dystrophy mice model: an uphill battle 2 Marine Theret1#, Marcela Low1#, Lucas Rempel1, Fang Fang Li1, Lin Wei Tung1, Osvaldo 3 Contreras3,4, Chih-Kai Chang1, Andrew Wu1, Hesham Soliman1,2, Fabio M.V. Rossi1 4 1School of Biomedical Engineering and the Biomedical Research Centre, Department of Medical 5 Genetics, 2222 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada 6 2Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Minia 7 University, Minia, Egypt 8 3Developmental and Stem Cell Biology Division, Victor Chang Cardiac Research Institute, 9 Darlinghurst, NSW, 2010, Australia 10 4Departamento de Biología Celular y Molecular and Center for Aging and Regeneration (CARE- 11 ChileUC), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331150 12 Santiago, Chile 13 # Denotes Co-first authorship 14 15 Keywords: drug screening, fibro/adipogenic progenitors, fibrosis, repair, skeletal muscle. 16 Correspondence to: 17 Marine Theret 18 School of Biomedical Engineering and the Biomedical Research Centre 19 University of British Columbia 20 2222 Health Sciences Mall, Vancouver, British Columbia 21 Tel: +1(604) 822 0441 fax: +1(604) 822 7815 22 Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427485; this version posted January 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Tyrosine Kinase Inhibitor, Vatalanib, Inhibits Proliferation and Migration of Human Pterygial Fibroblasts
    BASIC INVESTIGATION Tyrosine Kinase Inhibitor, Vatalanib, Inhibits Proliferation and Migration of Human Pterygial Fibroblasts Hong Kyu Kim, MD,* Ji-Young Choi, PhD,† Sang Min Park, PhD,‡ Chang Rae Rho, MD, PhD,§ Kyong Jin Cho, MD, PhD,¶ and Sangmee Ahn Jo, PhD‡k b significantly reduced, but there was no alteration in p53 protein Purpose: Vatalanib is a small-molecule tyrosine kinase inhibitor. levels in HPFs. We investigated the effects of vatalanib on the proliferation and migration of cultured human pterygial fibroblasts (HPFs). Conclusions: These results indicate that vatalanib significantly suppressed the proliferation and migration of HPFs by decreasing Methods: Pterygium tissues were obtained after pterygium exci- vascular endothelial growth factor and transforming growth factor-b. sion surgery and subjected to primary culture. HPFs were treated Vatalanib showed less toxicity than that of MMC. Based on these with vatalanib at various concentrations. Mitomycin C (MMC) was results, vatalanib may potentially serve as a new adjuvant treatment used as a positive control. Cell proliferation and migration assays after pterygium excision surgery. were used to investigate the effects of vatalanib. Cell death was measured using flow cytometry analysis. Western blot analysis was Key Words: tyrosine kinase inhibitor, vatalanib, mitomycin C, performed to identify signaling molecules associated with the pterygium, cell growth response to vatalanib. (Cornea 2017;36:1116–1123) Results: Vatalanib inhibited both proliferation and migration of HPFs in a dose-dependent manner. Cell proliferation was signif- m terygium is one of the most common ocular surface icantly suppressed by vatalanib (10 and 100 M) and MMC diseases. It is characterized by remodeling, proliferation, (0.004% and 0.04%) treatments.
    [Show full text]
  • Prognostic and Predictive Role of Lactate Dehydrogenase 5 ( LDH5) Expression in Colorectal Cancer Patients Treated with PTK787/Z
    Author Manuscript Published OnlineFirst on June 1, 2011; DOI: 10.1158/1078-0432.CCR-10-2918 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Prognostic and predictive role of lactate dehydrogenase 5 ( LDH5) expression in colorectal cancer patients treated with PTK787/ZK 222584 (Vatalanib) anti- angiogenic therapy. Short title: LDH5 and PTK/ZK in colorectal cancer 1 1 1 Michael I. Koukourakis, Alexandra Giatromanolaki, Efthimios Sivridis, 2 3 4 Kevin C. Gatter, Tanja Trarbach Gunnar Folprecht 5 5 6 7 Michael M. Shi , David Lebwohl , Tarja Jalava , Dirk Laurent 8 2 Gerold Meinhardt , Adrian L. Harris For the ‘Tumour and Angiogenesis Research Group’ 1 Departments of Pathology, and Radiotherapy/Oncology, Democritus University of Thrace, Alexandroupolis 68100, Greece Tel/Fax 0030-2551-31522, Email: [email protected] 2 Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine and Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, OX3 9DS, UK; Tel -44-1865-222457 Fax: -44-1865- 222431 E-mail: [email protected] 3 University of Essen, West German Cancer Center, Essen, Germany; [email protected] 4 University Hospital Dresden, Dresden, Germany; [email protected] 5 Novartis Pharmaceuticals Co, East Hanover, NJ, USA; [email protected] 6 ; Bayer Schering Pharma Oy, Espoo, Finland [email protected] 7 Bayer Healthcare Pharmaceuticals, Berlin, Germany; [email protected] 8 Bayer Healthcare Pharmaceuticals, NJ, USA, [email protected] Address for correspondence Michael I. Koukourakis, MD Department of Radiotherapy – Oncology Democritus University of Thrace Alexandroupolis 68100, Greece Tel; 25510-74628 Fax: 25510-30329 Email: [email protected] Downloaded from clincancerres.aacrjournals.org on September 23, 2021.
    [Show full text]
  • Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
    Published OnlineFirst September 20, 2013; DOI: 10.1158/2159-8290.CD-13-0350 RESEARCH ARTICLE Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia Tea Pemovska 1 , Mika Kontro 2 , Bhagwan Yadav 1 , Henrik Edgren 1 , Samuli Eldfors1 , Agnieszka Szwajda 1 , Henrikki Almusa 1 , Maxim M. Bespalov 1 , Pekka Ellonen 1 , Erkki Elonen 2 , Bjørn T. Gjertsen5 , 6 , Riikka Karjalainen 1 , Evgeny Kulesskiy 1 , Sonja Lagström 1 , Anna Lehto 1 , Maija Lepistö1 , Tuija Lundán 3 , Muntasir Mamun Majumder 1 , Jesus M. Lopez Marti 1 , Pirkko Mattila 1 , Astrid Murumägi 1 , Satu Mustjoki 2 , Aino Palva 1 , Alun Parsons 1 , Tero Pirttinen 4 , Maria E. Rämet 4 , Minna Suvela 1 , Laura Turunen 1 , Imre Västrik 1 , Maija Wolf 1 , Jonathan Knowles 1 , Tero Aittokallio 1 , Caroline A. Heckman 1 , Kimmo Porkka 2 , Olli Kallioniemi 1 , and Krister Wennerberg 1 ABSTRACT We present an individualized systems medicine (ISM) approach to optimize cancer drug therapies one patient at a time. ISM is based on (i) molecular profi ling and ex vivo drug sensitivity and resistance testing (DSRT) of patients’ cancer cells to 187 oncology drugs, (ii) clinical implementation of therapies predicted to be effective, and (iii) studying consecutive samples from the treated patients to understand the basis of resistance. Here, application of ISM to 28 samples from patients with acute myeloid leukemia (AML) uncovered fi ve major taxonomic drug-response sub- types based on DSRT profi les, some with distinct genomic features (e.g., MLL gene fusions in subgroup IV and FLT3 -ITD mutations in subgroup V). Therapy based on DSRT resulted in several clinical responses.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,945,572 B2 Chant Et Al
    USOO8945572B2 (12) United States Patent (10) Patent No.: US 8,945,572 B2 Chant et al. (45) Date of Patent: Feb. 3, 2015 (54) METHODS AND COMPOSITIONS FOR THE FOREIGN PATENT DOCUMENTS DAGNOSIS AND TREATMENT OF CANCER WO WO 1999/44062 9, 1999 WO OOf 46343 8, 2000 (75) Inventors: John Chant, Millbrae, CA (US); WO O3,024987 A1 3, 2003 Anthony S. Guerrero, San Francisco, WO 2005/066211 A2 7/2005 CA (US); Peter Haverty, San Francisco, WO WO 2005,115363 12/2005 CA (US); Cynthia Honchell, San WO 2006/110581 A2 10, 2006 Francisco, CA (US); Kenneth Jung, San WO 2007 134210 A2 11/2007 Francisco, CA (US); Thomas Wu, San OTHER PUBLICATIONS Francisco, CA (US) Gura (Science, 1997, 278: 1041-1042).* (73) Assignee: Genentech, Inc., South San Francisco, Kaiser (Science, 2006, 313: 1370).* CA (US) Gura (Science, 1995, 270:575-577).* Tockman et al (Cancer Res., 1992, 52:271 1s-2718s).* (*) Notice: Subject to any disclaimer, the term of this Pritzker (Clinical Chemistry, 2002, 48: 1147-1150).* patent is extended or adjusted under 35 Bai et al. (Cancer Res., 2010, 70: 7630-9).* Otte et al. (European Journal of Clinical Investigation, 2000, 30, U.S.C. 154(b) by 902 days. 222-229).* Yoshino et al. (Oncology Reports 2005, 13: 247-252).* (21) Appl. No.: 12/300,156 Eswarakumar et al., “Cellular signaling by fibroblast growth factor receptors' Cytokine Growth Factor Rev. 16(2): 139-49 (Apr. 2005). (22) PCT Filed: May 11, 2007 Miki et al., “Determination of ligand-binding specificity by alterna tive splicing: two distinct growth factor receptors encoded by a single (86).
    [Show full text]
  • Piperazine Are Toll-Like Receptor 4 Antagonists, Inhibit NF-Κb Activation, and Decrease TNF-Alpha Secretion in Primary Microglia
    Journal Pre-proof Mitoxantrone, pixantrone and mitoxantrone (2-hydroxyethyl)piperazine are toll-like receptor 4 antagonists, inhibit NF-κB activation, and decrease TNF-alpha secretion in primary microglia Maiju Rinne Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing , Kert Matlik¨ Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Supervision; Writing - review & editing , Tiina Ahonen Formal analysis; Validation; Writing - review & editing , Fabio Vedovi Conceptualization; Data curation; Formal analysis; Visualization; Roles/Writing - original draft; Writing - review & editing , Giovanni Zappia Conceptualization; Funding acquisition; Supervision; Writing - review & editing , Vaniaˆ M. Moreira Conceptualization; Funding acquisition; Supervision; Writing - review & editing , Jari Yli-Kauhaluoma Conceptualization; Funding acquisition; Project administration; Supervision; Writing - review & editing , Sakari Leino Formal analysis; Investigation; Visualization; Writing - review & editing , Outi Salminen Formal analysis; Investigation; Visualization; Writing - review & editing , Eija Kalso Conceptualization; Funding acquisition; Project administration; Supervision; Writing - review & editing , Mikko Airavaara Conceptualization; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Visualization; Roles/Writing - original draft; Writing - review &
    [Show full text]
  • Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
    Acute Myeloid Leukemia SUPPLEMENTARY APPENDIX Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia Heikki Kuusanmäki, 1,2 Aino-Maija Leppä, 1 Petri Pölönen, 3 Mika Kontro, 2 Olli Dufva, 2 Debashish Deb, 1 Bhagwan Yadav, 2 Oscar Brück, 2 Ashwini Kumar, 1 Hele Everaus, 4 Bjørn T. Gjertsen, 5 Merja Heinäniemi, 3 Kimmo Porkka, 2 Satu Mustjoki 2,6 and Caroline A. Heckman 1 1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki; 2Hematology Research Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki; 3Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland; 4Department of Hematology and Oncology, University of Tartu, Tartu, Estonia; 5Centre for Cancer Biomarkers, De - partment of Clinical Science, University of Bergen, Bergen, Norway and 6Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.214882 Received: December 17, 2018. Accepted: July 8, 2019. Pre-published: July 11, 2019. Correspondence: CAROLINE A. HECKMAN - [email protected] HEIKKI KUUSANMÄKI - [email protected] Supplemental Material Phenotype-based drug screening reveals an association between venetoclax response and differentiation stage in acute myeloid leukemia Authors: Heikki Kuusanmäki1, 2, Aino-Maija
    [Show full text]
  • Angiogenesis and Tumor Progression Inhibition of Cyclooxygenase-2 Selective Inhibitor Celecoxib Associated with Poly (Lactic-Co
    Int. J. Morphol., 35(2):733-739, 2017. Angiogenesis and Tumor Progression Inhibition of Cyclooxygenase-2 Selective Inhibitor Celecoxib Associated with Poly (lactic-co-glycolic acid) in Tumor Cell Line Resistant to Chemotherapy Inhibición de Angiogénesis y Progresión Tumoral por Inhibidor Selectivo de Ciclooxigenasa-2 Celecoxib Asociado con Ácido (poli láctico co-glicólico) en Línea de Células Tumorales Resistentes a Quimioterapia Ignacio Roa1.2,3; Mario Cantín4†; Cristian Vilos5; Carlos Rosas6 & David Lemus7 ROA, I.; CANTÍN, M.; VILOS, C.; ROSAS, C. & LEMUS, D. Angiogenesis and tumor progression inhibition of cyclooxygenase-2 selective inhibitor celecoxib associated with poly (lactic-co-glycolic acid) in tumor cell line resistant to chemotherapy. Int. J. Morphol., 35(2):733-739, 2017. SUMMARY: Although, antineoplastic therapies have now been developed reduction of tumor progression, it is necessary to find new therapeutic alternatives to suppress angiogenesis. Thus celecoxib (Cx) has been used for its antiangiogenic action in combination with certain polymeric compounds such as poly (lactic co-glycolic acid) (PLGA) acid, which help to improve the bioavailability and avoid effects of long drug administrations. For this purpose we used a murine tumor model induced by mammary adenocarcinoma cells resistant to chemotherapy (TA3-MTXR). CX/PLGA inhibits the microvascular density, VEGF expression and cell proliferation in addition to increased apoptosis (P <0.0001). Cx reduces tumor progression in a concentration of 1000 ppm associated with PLGA,
    [Show full text]
  • Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) As First-Line Treatment of Metastatic Colorectal Cancer: the RESPECT Trial
    Published OnlineFirst March 26, 2013; DOI: 10.1158/1078-0432.CCR-13-0107 Clinical Cancer Cancer Therapy: Clinical Research Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial Josep Tabernero1, Rocio Garcia-Carbonero3, James Cassidy5, Alberto Sobrero8, Eric Van Cutsem9, Claus-Henning Kohne€ 10, Sabine Tejpar9, Oleg Gladkov11, Irina Davidenko12, Ramon Salazar2, Liubov Vladimirova13, Sergey Cheporov14, Olga Burdaeva15, Fernando Rivera4, Leslie Samuel6, Irina Bulavina16, Vanessa Potter7, Yu-Lin Chang17, Nathalie A. Lokker17, and Peter J. O'Dwyer18 Abstract Purpose: This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sor- afenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC). Experimental Design: Patients were randomized to sorafenib (400 mg b.i.d.) or placebo, combined with mFOLFOX6 (oxaliplatin 85 mg/m2; levo-leucovorin 200 mg/m2; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion) every 14 days. Primary endpoint was progression-free survival (PFS). Target sample was 120 events in 180 patients for >85% power (two-sided a ¼ 0.20) to detect an HR ¼ 0.65. Results: Of 198 patients randomized, median PFS for sorafenib plus mFOLFOX6 was 9.1 months versus 8.7 months for placebo plus mFOLFOX6 (HR ¼ 0.88; 95% CI, 0.64–1.23; P ¼ 0.46). There was no difference between treatment arms for overall survival. Subgroup analyses of PFS and overall survival showed no difference between treatment arms by KRAS or BRAF status (mutant and wild type). The most common grade 3/4 adverse events in the sorafenib and placebo arms were neutropenia (48% vs.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,910,098 B2 Fuh Et Al
    USOO79100.98B2 (12) United States Patent (10) Patent No.: US 7,910,098 B2 Fuh et al. (45) Date of Patent: Mar. 22, 2011 (54) ANT-VEGF ANTIBODES FOREIGN PATENT DOCUMENTS CA 2 O19559 12/1990 (75) Inventors: Germaine Fuh, Pacifica, CA (US); EP O 368 684 9, 2004 Chingwei V. Lee, Foster City, CA (US) WO WO93, 1116.1 6, 1993 WO WO95/27062 10, 1995 WO WO97/.44453 11, 1997 (73) Assignee: Genentech, Inc., South San Francisco, WO WO 97/45450 12/1997 CA (US) WO WO 98.45331 10, 1998 WO WOOO,34337 6, 2000 WO WO 2005/O12359 2, 2005 (*) Notice: Subject to any disclaimer, the term of this WO WO 2005/044853 5, 2005 patent is extended or adjusted under 35 WO WO 2005/123104 12/2005 U.S.C. 154(b) by 32 days. OTHER PUBLICATIONS (21) Appl. No.: 12/315,220 Rudikoffetal, Proc Natl Acad Sci USA 79: 1979-1983, 1982.* Barrios et al. J Molecular Recognition 17: 332-338, 2004.* (22) Filed: Dec. 1, 2008 MacCallum et al., J Mol. Biol 262: 732-745, 1996.* Wu et al., J. Mol. Biol. 294: 151-162, 1999.* Pini et al., “Design and Use of a Phage Display Library: Human (65) Prior Publication Data Antibodies with Subnanomolar Affinity Against a Marker of US 2009/O142343 A1 Jun. 4, 2009 Angiogenesis Eluted From a Two-Dimensional Gel.” J. Biol. Chem. 273:21769-21776 (1998). Adamis et al., “Inhibition of Vascular Endothelial Growth Factor Related U.S. Application Data Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate.” Arch.
    [Show full text]
  • C'. Phsocfh (1C) OH
    US007087789B2 (12) United States Patent (10) Patent No.: US 7,087,789 B2 Prakash et al. (45) Date of Patent: Aug. 8, 2006 (54) METHODS FOR NUCLEOPHILC OTHER PUBLICATIONS FLUOROMETHYLATION Stahly, Nucleophilic Addition of Difluoromethyl Phenyl Sulfone to Aldehydes and Various Transformation of the (75) Inventors: issure Esthi, Resulting Alcohols, Journal of Fluorine Chemistry, 43, s s s 1989, 53-66.* E. i. 'S'srge A. Olah, Russell et al., Effective Nucleophilic Trifluoromethylation everly 1111s, with Fluoroform and Common Base, Tetrahedron, 54, 1998, Assignee: University of Southern California, 13771-13782.* - (73) Los Angeles, CA (US) Large et al., Nucleophilic Trifluoromethylation of Carbonyl s Compounds and Disulfides with Trifluoromethane and Sili (*) Notice: Subject to any disclaimer, the term of this con-Containing Bases with Fluoroform and Common Base, patent is extended or adjusted under 35 Snythesis, J. Org. Chem. 2000, 65, 8848-8856. U.S.C. 154(b) by 0 days. Prakash, G.K.S.; Krishnamurti, R.; Olah, G.A., J. Am. Chem. Soc. 1989, 111, 393-395. (21) Appl. No.: 10/755,902 (Continued) (22) Filed: Jan. 12, 2004 Primary Examiner Johann Richter O O Assistant Examiner Chukwuma Nwaonicha (65) P O PublicationDO Dat (74) Attorney, Agent, or Firm Winston & Strawn LLP US 2004/0230079 A1 Nov. 18, 2004 (57) ABSTRACT Related U.S. Application Data (60) Provisional application No. 60/440,011, filed on Jan. 13, 2003. A novel, convenient and efficient method for trifluoromethy s lation of substrate compounds is disclosed. Particularly, (51) Int. Cl. alkoxide and hydroxide induced nucleophilic trifluorom C07C 319/00 (2006.01) ethylation of carbonyl compounds, disulfides and other (52) U.S.
    [Show full text]
  • Chemistry of Trifluoroacetimidoyl Halides As Versatile Fluorine-Containing Building Bloks
    number 137 Contribution Chemistry of Trifluoroacetimidoyl Halides as Versatile Fluorine-containing Building Blocks Kenji Uneyama Professor of Emeritus, Department of Applied Chemistry, Okayama University Okayama 700-8530, Okayama, Japan 1. Outline of trifluoroacetimidoyl halides develop more sophisticated building blocks. They should be synthesized in high yields from easily available starting The trifluoromethyl group involved in organic compounds materials and should contain highly potential functional plays important roles as a key functional group in groups usable for further molecular modification. On this medicine, agricultural chemicals and electronic materials basis, trifluoroacetimidoyl halides are one of the unique and like liquid crystals. Common methods for introducing the valuable CF3-containing synthetic building blocks due to trifluoromethyl group (CF3 group) into organic compounds the following promising profiles; a) easy one-step are categorized into three; 1) the use of building blocks synthesis from a very available trifluoroacetic acid in containing CF3 group, 2) trifluoromethylation by the use of excellent yields, b) relatively stable to be stored, and c) trifluoromethylating agents such as CF3-TMS, FSO2CO2Me, containing highly potential functional groups such as CF3, CF3I, etc., and 3) the transformation of a functional group imino C=N double bond and halogen (Scheme 1). such as CCl3 and CO2H groups to CF3 group by the use of fluorinating agents such as F2 and HF. The method 3 is (Synthesis) conventionally used for the industrial mass production of Imidoyl halides 1 (X: Cl, Br) are synthesized from CF3-containing molecules, which are mostly structurally trifluoroacetic acid in excellent yields (85-95%) as shown 2) simple and stable molecules.
    [Show full text]